VLON · Vallon Pharmaceuticals
Acquired Company
Vallon Pharmaceuticals completed a merger with GRI Bio, Inc. on April 21, 2023, with the combined company to operate as GRI Bio, Inc. and the stock to trade under the ticker GRI beginning April 24, 2023.
Vallon Pharmaceuticals Inc. is a clinical-stage biopharmaceutical company, headquartered in Philadelphia, PA. The Company is focused on the development of new medications to help patients with central nervous system (CNS) disorders. The Company’s lead investigational product candidate, ADAIR, is a novel abuse deterrent formulation of amphetamine immediate release being developed for the treatment of ADHD and narcolepsy.
Market Cap
931.3M
52 Wk Range
N/A - N/A
Previous Close
$1.96
Open
$2.00
Volume
41,482
Day Range
$1.95 - $2.02
Enterprise Value
N/A
Cash
159.3M
Avg Qtr Burn
N/A
Insider Ownership
23.42%
Institutional Own.
13.28%
Qtr Updated
Mar 31st 2025